Firms, funds, people, portfolio companies and transactions from sworn filings and cited announcements, kept as a graph with a date and a source on every edge. Reported gross assets are never fund size, regulatory AUM is never dry powder, and a deal value prints only when someone disclosed it.

The names on this page are hidden. Create a free account and they fill in. No card, and every figure, date and source on this page is public either way.

Transactions / S••••

CapVest Completes Majority Acquisition of S••••

Platform acquisitionclosedannounced Mar 29, 2026closed Mar 29, 2026Fact
What happened
Platform
not an add-on on record
Control
Control
Share acquired
unknown
Industry
unknown
Target location
unknown
Seller kind
unknown
Rollover
unknown
Values, only where disclosed
Enterprise value
Not disclosed
Purchase price
Not disclosed
Equity value
Not disclosed
Target revenue
Not disclosed
Target EBITDA
Not disclosed
Multiple
Not disclosed
Parties and roles
4 named
Buy side
  • M••• F•••••Deal partnerconfirmed
    M••• F•••••, Partner at CapVest, said: “While we have worked to complete this transaction, the STADA team has continued to demonstrate strong growth across key regions and consumer healthcare, generics, biosimilars and innovative medicines.
  • Bad Vilbel, Germany and London, United Kingdom: C•••••• P••••••• L•• (“CapVest”), a leading global investment firm, today announces the completion of its acquisition of the majority stake in STADA Arzneimittel AG (“STADA” or the “Company”), a leading healthcare and pharmaceuticals company specializi
Side not stated
  • P•••• G•••••••••, Chief Executive Officer of STADA, commented: “We are delighted the transaction has now completed.
  • S••••Targetconfirmed
    CapVest Completes Majority Acquisition of S••••
Evidence
CapVest Completes Majority Acquisition of S••••
CapVest Completes Majority Acquisition of S•••• | Private Equity Intelligence | DFX